Gene expression: Protein interaction systems network modeling identifies transformation-associated molecules and pathways in ovarian cancer

Cancer Research

Volumn 70, Issue 12, 2010, Pages 4809-4819

  Bapat, Sharmila A ^a   Krishnan, Anagha ^b   Ghanate, Avinash D ^b   Kusumbe, Anjali P ^a   Kalra, Rajkumar S ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

^b UNIVERSITY OF PUNE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P53;

ARTICLE; CELL CYCLE; CELL TRANSFORMATION; CHROMOSOME ABERRATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA DAMAGE; DNA REPAIR; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE C MYC; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; RETINOBLASTOMA; SIGNAL TRANSDUCTION; TUMOR GENE; VALIDATION PROCESS;

CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; CYSTADENOCARCINOMA, SEROUS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION, FLUORESCENCE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; PROTEIN INTERACTION MAPPING; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 77953766711     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0447     Document Type: Article

References (43)

1. Swanton C, Caldas C. Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer 2009;100:1517-22.
2. Sotiriou C, Pusztai L. Gene expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
3. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
4. Lawrenson K, Gayther SA. Ovarian cancer: a clinical challenge that needs some basic answers. PLoS Med 2009;6:e25.
5. Bapat SA, Mali AM, Koppikar CB, et al. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005;65:3025-9.
6. McLendon R, Friedman A, Bigner D. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8. Available from: http://cancergenome.nih.gov.
7. Kilpinen S, Autio R, Ojala K, et al. Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783 samples from 175 types of healthy and pathological tissues. Genome Biol 2008;9:R139. Available from: http://www.genesapiens.org.
8. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
9. Margolin AA, Nemenman I, Basso K, et al. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 2006;7 Suppl 1:S7. Available from: http://gforge.nci.nih.gov/frs/ ?group-id=78.
10. Wu J, Vallenius T, Ovaska K, et al. Integrated network analysis platform for protein-protein interactions. Nat Methods 2009;6:75-7.
11. Kurrey NK, Jalgaonkar SP, Joglekar AV, et al. Snail and Slug mediate radio- and chemo-resistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009;27:2059-68.
12. Yasui DH, Peddada S, Bieda MC, et al. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. PNAS 2007;104:19416-21.
13. Thomas PD, Campbell MJ, Kejariwal A, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 2003;13:2129-41. Available from: http://www.pantherdb.org/tools/compareToRefListForm.jsp. (Pubitemid 37161770)
14. Wani AA, Sharma N, Shouche YS, et al. Nuclear-mitochondrial genomic profiling reveals a pattern of evolution in epithelial ovarian tumor stem cells. Oncogene 2006;25:6336-44. (Pubitemid 44564749)
15. Kusumbe AP, Mali AM, Bapat SA. CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Stem Cells 2009;27:498-508.
16. Kusumbe AP, Bapat SA. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 2009;69:9245-53.
17. Staebler A, Karberg B, Behm J, et al. Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Genes Chromosomes Cancer 2006;45:905-17.
18. Fejzo MS, Dering J, Ginther C, et al. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target. Genes Chromosomes Cancer 2008;47:873-83.
19. Takano M, Kudo K, Goto T, et al. Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer. Hum Cell 2001;14:267-71.
20. Scotto L, Narayan G, Nandula SV, et al. Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer 2008;47:755-65.
21. Ghoussaini M, Song H, Koessler T, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst 2008;100:962-6.
22. Pomerantz MM, Ahmadiyeh N, Jia L, et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet 2009;41:882-4.
23. Li Y, Meng G, Guo QN. Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. Exp Mol Pathol 2008;84:234-9.
24. Yamamoto A, Sakurai H. The DNA-binding domain of yeast Hsf1 regulates both DNA-binding and transcriptional activities. Biochem Biophys Res Commun 2006;346:1324-9. (Pubitemid 43946838)
25. Lin M, Morrison CD, Jones S, et al. Copy number gain and oncogenic activity of YWHAZ/14-3-3ζ in head and neck squamous cell carcinoma. Int J Cancer 2009;125:603-11.
26. Ishikawa N, Takano A, Yasui W, et al. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res 2007;67:11601-11.
27. Vucic EA, Brown CJ, Lam WL. Epigenetics of cancer progression. Pharmacogenomics 2008;9:215-34.
28. Chan TA, Glockner S, Yi JM, et al. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. Plos Med 2008;5:e114. (Pubitemid 351760910)
29. Ohm JE, McGarvey KM, Yu X, et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007;39:237-42.
30. Lee PS, Teaberry VS, Bland AE, et al. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. Int J Cancer 2009;26:1378-89.
31. Berchuck A, Iversen ES, Luo J, et al. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res 2009;15:2448-55.
32. Nakanishi H, Suda T, Katoh M, et al. Loss of imprinting of PEG1/ MEST in lung cancer cell lines. Oncol Rep 2004;12:1273-8.
33. Dekel B, Metsuianim S, Schmidt-Ott KM, et al. Multiple imprinted and stemness genes provide a link between normal and tumor progenitor cells of the developing human kidney. Cancer Res 2006;66:6040-9.
34. Sadr-Nabavi A, Ramser J, Volkmann J, et al. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 2009;124:1727-35.
35. Wang Y, Hayakawa J, Long F, et al. "Promoter array" studies identify cohorts of genes directly regulated by methylation, copy number change, or transcription factor binding in human cancer cells. Ann N Y Acad Sci 2005;1058:162-85.
36. Frigola J, Munoz M, Clark SJ, et al. Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy. Oncogene 2005;24:7320-6. (Pubitemid 41622236)
37. Pontén F, Jirström K, Uhlen M. The Human Protein Atlas-a tool for pathology. J Pathol 2008;216:387-93. Available from: http://www. proteinatlas.org.
38. Yan T, Schupp JE, Hwang HS, et al. Loss of DNA mismatch repair imparts defective cdc2 signaling and G([2]) arrest responses without altering survival after ionizing radiation. Cancer Res 2001;61:8290-7.
39. Kulkarni AA, Kingsbury SR, Tudzarova S, et al. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma. Clin Cancer Res 2009;15:2417-25.
40. Biswas S, Trobridge P, Romero-Gallo J, et al. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor β resistant cells. Genes Chromosomes Cancer 2008;47:95-106.
41. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
42. Peiró G, Diebold J, Löhrs U. CAS (cellular apoptosis susceptibility) gene expression in ovarian carcinoma: Correlation with 20q13.2 copy number and cyclin D1, p53, and Rb protein expression. Am J Clin Pathol 2002;118:922-9.
43. Zhou Z, Flesken-Nikitin A, Corney DC, et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 2006;66:7889-98. (Pubitemid 44299151)